Spinal muscular atrophy therapy reference (2026)

Spinal muscular atrophy therapy in 2026 organises around three approved disease-modifying options plus emerging combinations.

Approved options.

Nusinersen (intrathecal antisense oligonucleotide that increases SMN protein production from the SMN2 backup gene): given as loading doses then maintenance every four months. Indicated across the SMA age and severity spectrum.

Onasemnogene abeparvovec (one-time intravenous AAV gene therapy delivering a working SMN1 gene): typically given to children under two years of age based on weight-based dosing limits.

Risdiplam (oral SMN2 splicing modifier taken daily): indicated across the age spectrum, attractive for the oral delivery profile and for reaching patients without easy access to intrathecal procedures.

Newborn screening. SMA is now part of the newborn screening panel in most US states and in expanding EU jurisdictions. Newborn-screened presymptomatic infants treated within the first weeks of life have substantially better motor outcomes than those treated symptomatically.

Emerging combination strategies. Combinations of gene therapy plus chronic SMN-modifier therapy are in active investigation; the rationale is that one-time gene therapy may not produce sufficient lifetime SMN protein in all patients, and chronic SMN-modifier therapy on top may extend the benefit. Trial readouts are expected over the next 18 to 24 months.